Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis
During the 48-week extension study, 1.4% of previously randomized subjects experienced a culture-positive recurrence of symptomatic vulvovaginal candidiasis, demonstrating a continued long-term protective effect of oteseconazole.
Authors
- Stacey Curelop (ORCID: https://orcid.org/0000-0002-3622-6357)
- Ryan Sobel (ORCID: https://orcid.org/0000-0002-1959-2910)
- Stephen Brand (ORCID: https://orcid.org/0000-0002-1796-5584)
- Jack D. Sobel (ORCID: https://orcid.org/0000-0002-5589-4609)
- Samuel Lederman
Institutions
- Thomas Jefferson University (US)
- Wayne State University (US)
- New Covenant International (US)
- Mycovia Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Women s Health
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1177/15409996251394811
- Citations
- 1
- Primary Topic
- Reproductive tract infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.18